Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the âOfferingâ) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The Companyâs shares of common stock are expected to begin trading on the Nasdaq Capital Market on August 26, 2025, under the ticker symbol "CURX."
Related Questions
How does the $4.00 IPO price and $15âŻmillion raise affect CURX's valuation and potential upside compared to similar biotech IPOs?
What are the expected useâofâproceeds and how will the capital deployment timeline impact Curanex's pipeline milestones and cash runway?
What is the anticipated postâIPO share float and dilution, and how might that influence liquidity and shortâterm price volatility on the Nasdaq Capital Market?